- Home
- FORA vs IMMX Comparison
FORA vs IMMX Comparison
Compare FORA & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- IMMX
- Stock Information
- Founded
- FORA 2014
- IMMX 2014
- Country
- FORA United States
- IMMX United States
- Employees
- FORA N/A
- IMMX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- FORA Technology
- IMMX Health Care
- Exchange
- FORA Nasdaq
- IMMX Nasdaq
- Market Cap
- FORA 60.2M
- IMMX 65.5M
- IPO Year
- FORA N/A
- IMMX 2021
- Fundamental
- Price
- FORA $2.28
- IMMX $2.04
- Analyst Decision
- FORA Strong Buy
- IMMX Strong Buy
- Analyst Count
- FORA 1
- IMMX 1
- Target Price
- FORA $5.00
- IMMX $8.00
- AVG Volume (30 Days)
- FORA 73.0K
- IMMX 182.4K
- Earning Date
- FORA 11-12-2025
- IMMX 11-11-2025
- Dividend Yield
- FORA N/A
- IMMX N/A
- EPS Growth
- FORA N/A
- IMMX N/A
- EPS
- FORA N/A
- IMMX N/A
- Revenue
- FORA $25,031,040.00
- IMMX N/A
- Revenue This Year
- FORA $47.82
- IMMX N/A
- Revenue Next Year
- FORA $10.11
- IMMX N/A
- P/E Ratio
- FORA N/A
- IMMX N/A
- Revenue Growth
- FORA 18.59
- IMMX N/A
- 52 Week Low
- FORA $1.64
- IMMX $1.26
- 52 Week High
- FORA $4.03
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- FORA 61.78
- IMMX 39.54
- Support Level
- FORA $2.20
- IMMX $2.09
- Resistance Level
- FORA $2.38
- IMMX $2.34
- Average True Range (ATR)
- FORA 0.15
- IMMX 0.15
- MACD
- FORA 0.03
- IMMX 0.00
- Stochastic Oscillator
- FORA 78.43
- IMMX 16.67
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.